Welcome to our dedicated page for Callan JMB SEC filings (Ticker: CJMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Callan JMB Inc. filings document the public-company record of a Nevada corporation operating in healthcare logistics, cold-chain fulfillment, emergency preparedness support and pharmaceutical supply-chain services. The company’s Form 8-K reports furnish operating results, business updates, Regulation FD investor materials, material agreements and amendments to common stock purchase arrangements.
Registration statements describe the company’s securities offering, business disclosures, capital structure and risk factors. Proxy materials cover annual-meeting procedures, stockholder voting matters and governance. Recent current reports also document Nasdaq continued-listing compliance matters, including disclosures related to the stockholders’ equity standard for The Nasdaq Capital Market.
Callan JMB Inc. filed a Preliminary Information Statement (PRE 14C) that includes signature pages dated October 3, 2025 and a partial disclosure of executive names, titles, and select cash compensation figures for 2023–2024. The document lists Wayne Williams as Chief Executive Officer, President, and Chairman and shows signatures by Mr. Williams. Reported cash or total compensation line items include $5,896,896, $5,596,896, $832,063, $1,800,000, $102,885, and $171,739, shown alongside individual names such as David J. Croyle, M.D., Eric Kash, Shannon Badger, and others. The filing appears to be a short, partial extract focused on signatures and selected compensation rows rather than a full narrative or complete financial statement.
Callan JMB Inc. filed a Preliminary Information Statement (PRE 14C) that includes signature pages dated October 3, 2025 and a partial disclosure of executive names, titles, and select cash compensation figures for 2023–2024. The document lists Wayne Williams as Chief Executive Officer, President, and Chairman and shows signatures by Mr. Williams. Reported cash or total compensation line items include $5,896,896, $5,596,896, $832,063, $1,800,000, $102,885, and $171,739, shown alongside individual names such as David J. Croyle, M.D., Eric Kash, Shannon Badger, and others. The filing appears to be a short, partial extract focused on signatures and selected compensation rows rather than a full narrative or complete financial statement.
Callan JMB Inc. filed Amendment No. 1 to its Form S-1 registration statement as an exhibits-only update. The amendment leaves the main prospectus and prior disclosure unchanged, focusing instead on updating and organizing exhibits that support the registration.
The filing lists key corporate documents such as articles of incorporation, bylaws, major contracts, lease agreements, equity incentive and employment agreements, as well as an equity purchase agreement and related registration rights agreement with an investor. It also includes consents, a list of subsidiaries, governance policies, and an executive compensation clawback policy, and is signed by the company’s chief executive officer and other senior officers and directors.
Callan JMB Inc. filed Amendment No. 1 to its Form S-1 registration statement as an exhibits-only update. The amendment leaves the main prospectus and prior disclosure unchanged, focusing instead on updating and organizing exhibits that support the registration.
The filing lists key corporate documents such as articles of incorporation, bylaws, major contracts, lease agreements, equity incentive and employment agreements, as well as an equity purchase agreement and related registration rights agreement with an investor. It also includes consents, a list of subsidiaries, governance policies, and an executive compensation clawback policy, and is signed by the company’s chief executive officer and other senior officers and directors.
Callan JMB Inc. filed Amendment No. 1 to its Form S-1 registration statement as an exhibits-only update. The amendment leaves the main prospectus and prior disclosure unchanged, focusing instead on updating and organizing exhibits that support the registration.
The filing lists key corporate documents such as articles of incorporation, bylaws, major contracts, lease agreements, equity incentive and employment agreements, as well as an equity purchase agreement and related registration rights agreement with an investor. It also includes consents, a list of subsidiaries, governance policies, and an executive compensation clawback policy, and is signed by the company’s chief executive officer and other senior officers and directors.
Callan JMB Inc. completed an initial public offering in February 2025, issuing 1,280,000 shares at $4.00 and a ~164,000 share overallotment for total gross proceeds of ~$5.78 million and net proceeds of approximately $4.7 million after underwriting discounts. The company issued underwriter warrants (72,179) and recognized equity-classified warrants in additional paid-in capital.
The company reported significant operating losses: six-month and year-to-date losses before income taxes of $(2.64M) and $(1.40M) in comparative periods, and net loss per share (basic and diluted) of $(0.87) based on 2,630,137 weighted average shares. Cash decreased materially (e.g., decreases of $3.06M and $1.04M in periods shown). Balance sheet shows increased equity after IPO, material operating lease liabilities and right-of-use assets, and deferred tax assets primarily from NOLs.